Author(s):
Nermeen N. Abuelsoud, Fatma H. Abdelraouf
Email(s):
nersoud09@gmail.com , fatma.hassan@kasralainy.edu.eg
DOI:
10.52711/0974-360X.2025.00124 
Address:
Nermeen N. Abuelsoud1, Fatma H. Abdelraouf2
1Department of Pharmacy Practice, Faculty of Pharmacy, Heliopolis University for Sustainable Development, Cairo, Egypt.
2Department of Chemical and Clinical Pathology, Kasr Alaini University Hospital, Faculty of Medicine, Cairo University, Cairo, Egypt.
*Corresponding Author
Published In:
Volume - 18,
Issue - 2,
Year - 2025
ABSTRACT:
Background: There is a clear decrease in the control rates of high blood pressure in Egyptian patients, so it is necessary to reveal the hidden causes responsible for this problem through extensive studies of these reasons. The prevalence of resistant hypertension among adults with treated hypertension ranged from 34% to 39%. African descent ethnic groups are more likely to develop hypertension and the organ damage that goes along with it at younger ages. They are also more likely to have kidney disease, stroke, heart failure, and mortality. Angiotensin-converting enzyme-2 rs2106809 is a significant predictor of the response to antihypertensive treatment with Angiotensin-converting enzyme inhibitors. The purpose of this study was to determine the genetic and clinical factors that may contribute to resistance hypertension in Egyptian patients through detecting the drug-drug and drug-disease (hypertension) interactions, together with the relationship between Angiotensin-converting enzyme -2 rs2106809 genetic variations and the antihypertensive effects of 31 antihypertensive medications from many pharmacological categories. Methods: Patients received a total of 306 antihypertensive medications. All patients’ medical records were reviewed to detect all patients’ medications, comorbidities and other patients’ characteristics (age, sex, body weight, electrolytes, fasting blood sugar levels, lipid profiles and cardiac and kidney function tests) that may affect blood pressure control. Results: A total of 306 patients (68 males and 238 females) who attended Kasr Alainy Rheumatology Outpatient Clinic were enrolled in the study, they received 31 antihypertensive medications. There was a statistically significant difference between the different genotypes and blood pressure control. All detected drug – drug interactions were recorded and a total of 235 drug interactions were discovered. The detected drug – drug interactions were classified as interactions that increase the antihypertensive effect (90 types) or interactions that decrease the antihypertensive effect (224 types). Almost all patients (99.7%) received drugs that decrease blood pressure while about 57% of patients received drugs that increase blood pressure. All factors that may affect blood pressure control were detected and there was a statistically significant difference between the different genotypes and the number of drugs increasing blood pressure and serum calcium levels. Conclusions: Previous studies were focused on age, higher baseline blood pressure, obesity, excessive salt intake, diabetes, left ventricular hypertrophy, black race, female sex, and measurements of the renin–angiotensin–aldosterone system as the main causes of interindividual variabilities. This study documented that drug – drug, drug – disease interactions and different genetic polymorphisms are more serious and important causes for these variabilities.
Cite this article:
Nermeen N. Abuelsoud, Fatma H. Abdelraouf. The effect of genetic polymorphisms, drug-disease and drug-drug interactions on hypertension control in Egyptian patients. Research Journal of Pharmacy and Technology.2025;18(2):839-1. doi: 10.52711/0974-360X.2025.00124
Cite(Electronic):
Nermeen N. Abuelsoud, Fatma H. Abdelraouf. The effect of genetic polymorphisms, drug-disease and drug-drug interactions on hypertension control in Egyptian patients. Research Journal of Pharmacy and Technology.2025;18(2):839-1. doi: 10.52711/0974-360X.2025.00124 Available on: https://rjptonline.org/AbstractView.aspx?PID=2025-18-2-56
REFERENCES:
1. Hasan DM, Emeash AH, Mustafa SB, Abdelazim GA, Alaa El-din A. Hypertension control: a systematic review. Current Hypertension Reviews. 2014; 10(3): 134-41 doi: 10.2174/1573402111666141217111807
2. Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, et al. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. Hypertension. 2018;72(5):e53-e90. doi: 10.1161/HYP.0000000000000084.
3. Smith SM, Gong Y, Handberg E, Messerli FH, Bakris GL, Ahmed A, et al. Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. J Hypertens. 2014; 32: 635–643 doi: 10.1097/HJH.0000000000000051
4. Sim JJ, Bhandari SK, Shi J, Reynolds K, Calhoun DA, Kalantar-Zadeh K, et al. Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension. Kidney Int. 2015; 88:622–632. doi: 10.1038/ki.2015.1
5. Egan BM, Kai B, Wagner CS, Henderson JH, Chandler AH, Sinopoli A. Blood pressure control provides less cardiovascular protection in adults with than without apparent treatment-resistant hypertension. J Clin Hypertens (Greenwich). 2016; 18: 817–824. doi: 10.1111/jch.12773
6. Sim JJ, Bhandari SK, Shi J, Liu IL, Calhoun DA, McGlynn EA, et al. Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system. Mayo Clin Proc. 2013; 88: 1099–1107. doi: 10.1016/j.mayocp.2013.06.017
7. Hwang AY, Dave C, Smith SM. Trends in antihypertensive medication use among US patients with resistant hypertension, 2008 to 2014. Hypertension. 2016; 68: 1349–1354. doi: 10.1161/HYPERTENSIONAHA.116.08128
8. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020; Jun; 75(6): 1334-1357. doi: 10.1161/HYPERTENSIONAHA.120.15026.
9. Patnaik M, Pati P, Swain SN, Mohapatra MK, Dwibedi B, Kar SK, et al. Association of angiotensin-converting enzyme and angiotensin-converting enzyme-2 gene polymorphisms with essential hypertension in the population of Odisha, India. Ann Hum Biol 2014; 41: 145–152 doi: 10.3109/03014460.2013.837195
10. Chen YY, Liu D, Zhang P, Zhong JC, Zhang CJ, Wu SL, et al. Impact of ACE2 gene polymorphism on antihypertensive efficacy of ACE inhibitors. J Hum Hypertens. 2016; 30(12): 766-771. doi: 10.1038/jhh.2016.24.
11. Rice GI, Jones AL, Grant PJ, Carter AM, Turner AJ, Hooper NM. Circulating activities of angiotensin-converting enzyme, its homolog, angiotensin-converting enzyme 2, and neprilysin in a family study. Hypertension 2006; 48: 914–920. doi: 10.1161/01.HYP.0000244543.91937.79
12. de Jager RL, van Maarseveen EM, Bots ML, Blankestijn PJ; SYMPATHY investigators. Medication adherence in patients with apparent resistant hypertension: findings from the SYMPATHY trial. Br J Clin Pharmacol. 2018; 84(1): 18-24. doi: 10.1111/bcp.13402.
13. Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens Res. 2019; 42(9): 1235-1481. doi: 10.1038/s41440-019-0284-9.
14. Drug Interactions Checker – Medscape. Drug Reference Database https://reference.medscape.com/drug-interactionchecker. Accessed 15 Jan 2021
15. Lexicomp: Interactions. https://online.lexi.com/lco/action/interact. Accessed 15 Jan 2021
16. Vasdev S, Singal P, Gill V. The antihypertensive effect of cysteine. Int J Angiol. 2009; 18(1): 7-21. doi: 10.1055/s-0031-1278316.
17. Beattie CJ, Fulton RL, Higgins P, Padmanabhan S, McCallum L, Walters MR, et al. Allopurinol initiation and change in blood pressure in older adults with hypertension. Hypertension. 2014; 64(5): 1102-7. doi: 10.1161/HYPERTENSIONAHA.114.03953.
18. Yilmaz S, Pekdemir M, Tural U, Uygun M. Comparison of alprazolam versus captopril in high blood pressure: a randomized controlled trial. Blood Press. 2011;20(4):239-43. doi: 10.3109/08037051.2011.553934.
19. Piotrowski R, Giebułtowicz J, Baran J, Sikorska A, Gralak-Łachowska D, Soszyńska M, et al. Antazoline-insights into drug-induced electrocardiographic and hemodynamic effects: Results of the ELEPHANT II substudy. Ann Noninvasive Electrocardiol. 2017;22(5): e12441. doi: 10.1111/anec.12441.
20. Milionis HJ, Liberopoulos EN, Achimastos A, Elisaf MS, Mikhailidis DP. Statins: another class of antihypertensive agents? J Hum Hypertens. 2006; 20(5): 320-35. doi: 10.1038/sj.jhh.1002001.
21. Hermida RC, Fernández JR, Ayala DE, Mojón A, Iglesias M. Influence of aspirin usage on blood pressure: dose and administration-time dependencies. Chronobiol Int. 1997; 14(6): 619-37. doi: 10.3109/07420529709001452
22. Mendelson N, Gontmacher B, Vodonos A, Novack V, Abu-AjAj M, Wolak A, et al. Benzodiazepine consumption is associated with lower blood pressure in ambulatory blood pressure monitoring (ABPM): Retrospective Analysis of 4938 ABPMs. Am J Hypertens. 2018; 31(4): 431-437. doi: 10.1093/ajh/hpx188.
23. McCarron DA, Morris CD. Blood pressure response to oral calcium in persons with mild to moderate hypertension. A randomized, double-blind, placebo-controlled, crossover trial. Ann Intern Med. 1985; 103(6): 825-31. doi: 10.7326/0003-4819-103-6-825.
24. Nagai T, Sakamoto K, Munechika K, Kubota Y, Inagaki K. Changes in Blood Pressure after the First Dose of Calcitonin (Elcatonin). The Showa University Journal of Medical Sciences. 2013; 25: 277-282. doi:10.15369/SUJMS.25.277
25. Kristal-Boneh E, Froom P, Harari G, Ribak J. Association of calcitriol and blood pressure in normotensive men. Hypertension. 1997; 30(5): 1289-94. doi: 10.1161/01.hyp.30.5.1289.
26. Tamás P, Csermely T, Ertl T, Vizer M, Szabó I, Prievara FT. Calcium dobesilate lowers the blood pressure in mild to moderate midtrimester hypertension: a pilot study. Gynecol Obstet Invest. 1999; 47(3): 210-3. doi: 10.1159/000010080.
27. Ke Y, Fu LL, Hong XF, Dong R, Xu TM, Guo JF, et al. Acute clenbuterol induces hypotension, atrioventricular block and cardiac asystole in the rabbit. Cardiovasc Toxicol. 2013; 13(1): 85-90. doi: 10.1007/s12012-012-9185-8.
28. Kirch C, Grossmann M, Fischer S, Neumeister V, Kirch W. Effect of digoxin on circadian blood pressure values in patients with congestive heart failure. Eur J Clin Invest. 2000; 30(4): 285-9. doi: 10.1046/j.1365-2362.2000.00627.x.
29. Mohamad Razi ZR, Schindler AE. Review on role of progestogen (dydrogesterone) in the prevention of gestational hypertension. Horm Mol Biol Clin Investig. 2016; 1; 27(2): 73-6. doi: 10.1515/hmbci-2015-0070.
30. Ashraf MS, Vongpatanasin W. Estrogen and hypertension. Current Hypertension Reports. 2006; 8(5): 368-376. doi:10.1007/S11906-006-0080-1
31. Gunawardhana L, McLean L, Punzi HA, Hunt B, Palmer RN, Whelton A, et al. Effect of febuxostat on ambulatory blood pressure in subjects with hyperuricemia and hypertension: a phase 2 randomized placebo-controlled study. J Am Heart Assoc. 2017; 6(11): e006683. doi: 10.1161/JAHA.117.006683.
32. Gilbert K, Nian H, Yu C, Luther JM, Brown NJ. Fenofibrate lowers blood pressure in salt-sensitive but not salt-resistant hypertension. J Hypertens. 2013; 31(4): 820-9. doi: 10.1097/HJH.0b013e32835e8227.
33. Borghi C, Dormi A, Veronesi M, Immordino V, Ambrosioni E. Use of lipid-lowering drugs and blood pressure control in patients with arterial hypertension. J Clin Hypertens (Greenwich). 2002; 4(4): 277-85. doi: 10.1111/j.1524-6175.2002.00499.x.
34. Chen HH, Li YD, Cheng PW, Fang YC, Lai CC, Tseng CJ, et al. Gabapentin reduces blood pressure and heart rate through the nucleus tractus solitarii. Acta Cardiol Sin. 2019; 35(6): 627-633. doi: 10.6515/ACS.201911_35(6).20190429B.
35. Shimada M, Hasegawa T, Nishimura C, Kan H, Kanno T, Nakamura T, Matsubayashi T. Anti-hypertensive effect of gamma-aminobutyric acid (GABA)-rich Chlorella on high-normal blood pressure and borderline hypertension in placebo-controlled double blind study. Clin Exp Hypertens. 2009;31(4):342-54. doi: 10.1080/10641960902977908.
36. Quintero C, Molano MF, Amaya S, Maya JJ, Andrade MJ. Cardiovascular effects of hyoscine butylbromide in patients under general anaesthesia. J Perioper Pract. 2022:17504589211072698. doi: 10.1177/17504589211072698.
37. Filho AG, Kinote A, Pereira DJ, Rennó A, dos Santos RC, Ferreira-Melo SE, et al. Infliximab prevents increased systolic blood pressure and upregulates the AKT/eNOS pathway in the aorta of spontaneously hypertensive rats. Eur J Pharmacol. 2013;700(1-3):201-9. doi: 10.1016/j.ejphar.2012.11.059.
38. Simko F, Baka T. Ivabradine and Blood Pressure Reduction: Underlying Pleiotropic Mechanisms and Clinical Implications. Front Cardiovasc Med. 2021; 8: 607998. doi: 10.3389/fcvm.2021.607998.
39. Doursout MF, Horton H, Hoang L, Liang Y, Hwang SA, Boyd S, et al. Lactoferrin moderates LPS-induced hypotensive response and gut injury in rats. Int Immunopharmacol. 2013; 15(2): 227-31. doi: 10.1016/j.intimp.2012.12.009.
40. He W, Li S, Zhang JA, Zhang J, Mu K, Li XM. Effect of levothyroxine on blood pressure in patients with subclinical hypothyroidism: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2018; 9: 454. doi: 10.3389/fendo.2018.00454.
41. Riad W, Moussa A. Lornoxicam attenuates the haemodynamic responses to laryngoscopy and tracheal intubation in the elderly. Eur J Anaesthesiol. 2008; 25(9): 732-6. doi: 10.1017/S0265021508004286
42. Hamidi Shishavan M, Henning RH, van Buiten A, Goris M, Deelman LE, Buikema H. Metformin improves endothelial function and reduces blood pressure in diabetic spontaneously hypertensive rats independent from glycemia control: comparison to vildagliptin. Sci Rep. 2017; 7(1): 10975. doi: 10.1038/s41598-017-11430-7.
43. Hoigné R, Zoppi M, Sollberger J, Hess T, Fritschy D. Fall in systolic blood pressure due to metamizol (dipyrone, noramidopyrine, novaminsulfone). Results from the Comprehensive Hospital Drug Monitoring Berne (CHDMB). Agents Actions Suppl. 1986;19:189-95. PMID: 3463177.
44. Zhang X, Li Y, Del Gobbo LC, Rosanoff A, Wang J, Zhang W, et al. Effects of Magnesium Supplementation on Blood Pressure: A Meta-Analysis of Randomized Double-Blind Placebo-Controlled Trials. Hypertension. 2016; 68(2): 324-33. doi: 10.1161/HYPERTENSIONAHA.116.07664.
45. Mangoni AA, Baghdadi LR, Shanahan EM, Wiese MD, Tommasi S, Elliot D, et al. Methotrexate, blood pressure and markers of arterial function in patients with rheumatoid arthritis: a repeated cross-sectional study. Ther Adv Musculoskelet Dis. 2017; 9(9): 213-229. doi: 10.1177/1759720X17719850.
46. Moes AD, Severs D, Verdonk K, van der Lubbe N, Zietse R, Danser AHJ, et al. Mycophenolate Mofetil Attenuates DOCA-Salt Hypertension: Effects on Vascular Tone. Front Physiol. 2018; 9: 578. doi: 10.3389/fphys.2018.00578.
47. Levenson J, Bouthier J, Chau NP, Roland E, Simon AC. Effects of nicorandil on arterial and venous vessels of the forearm in systemic hypertension. Am J Cardiol. 1989; 63(21): 40J-43J. doi: 10.1016/0002-9149(89)90203-8.
48. Scalco MZ, Serro-Azul JB, Giorgi D, Almeida OP, Wajngarten M. Effect of nortriptyline on the day-night systolic blood pressure difference in hypertensive and normotensive elderly depressed women. Am J Cardiol. 2003; 91(10): 1279-81.
49. Sahebkar A, Simental-Mendía LE, Kovanen PT, Pedone C, Simental-Mendía M, Cicero AFG. Effects of orlistat on blood pressure: a systematic review and meta-analysis of 27 randomized controlled clinical trials. J Am Soc Hypertens. 2018; 12(2): 80-96.
50. Buchanan TA, Meehan WP, Jeng YY, Yang D, Chan TM, Nadler JL, et al. Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect. J Clin Invest. 1995; 96(1): 354-60.
51. Jianzhi S, Qizeng W, Bin L, Wenhui L, Yunpeng C, Chenrong F, et al. Piperazine ferulate exerts antihypertensive effect and improves endothelial function in vitro and in vivo via the activation of endothelial nitric oxide synthase. Cell Mol Biol (Noisy-le-grand). 2019; 65(3) 119-124. doi:10.14715/cmb/2019.65.3.18
52. Zhang P, Li Y, Nie K, Wang L, Zhang Y. Hypotension and bradycardia, a serious adverse effect of piribedil, a case report and literature review. BMC Neurol. 2018;18(1):221. doi: 10.1186/s12883-018-1230-1.
53. Filippini T, Violi F, D'Amico R, Vinceti M. The effect of potassium supplementation on blood pressure in hypertensive subjects: A systematic review and meta-analysis. Int J Cardiol. 2017;230:127-135.
54. Kawano H, Yano K. Pravastatin decreases blood pressure in hypertensive and hypercholesterolemic patients receiving antihypertensive treatment. Circ J. 2006; 70(9): 1116-21. doi: 10.1253/circj.70.1116.
55. Seki S, Hashimoto K, Taniguchi I, Yoshimura M, Takeda N. Effect of rosuvastatin on systemic blood pressure in patients with hypercholesterolemia. Exp Clin Cardiol. 2012; 17(4): 221-5. PMID: 23592940; PMCID: PMC3627279.
56. Vardi Y, Klein L, Nassar S, Sprecher E, Gruenwald I. Effects of sildenafil citrate (viagra) on blood pressure in normotensive and hypertensive men. Urology. 2002;59(5):747-52. doi: 10.1016/s0090-4295(02)01510-8.
57. Ota KS. Probable valproate sodium-associated hypotension. The American Journal of Geriatric Pharmacotherapy. 2010;8(3):281-284. doi: 10.1016/j.amjopharm.2010.04.005.
58. Gyrd-Hansen N, Rasmussen F, Smith M. Cardiovascular effects of intravenous administration of tetracycline in cattle. J Vet Pharmacol Ther. 1981; 4(1): 15-25. doi: 10.1111/j.1365-2885.1981.tb00705.x.
59. Ma J, Liu H, Qiao Z, Cheng W, Wang H. Trimetazidine treatment influence on pressure overload induced ventricular remodeling and heart failure in rats. African Journal of Microbiology Research. 2012; 6(17): 3948-3955 doi:10.5897/AJMR12.409
60. Williams JC, Falcone RC, Do ML, Lindstrom DD, Howe BB. Acute blood pressure effects of selected serine proteases in normotensive rats and dogs. Pharmacology. 1991; 43(4): 199-209.
61. Qi Y, Aranda JM, Rodriguez V, Raizada MK, Pepine CJ. Impact of antibiotics on arterial blood pressure in a patient with resistant hypertension - A case report. Int J Cardiol. 2015; 201: 157-8.
62. El-Naggar AR, Zaafar D, Elyamany M, Hassanin S, Bassyouni A, Abdel-Latif H. The role of vildagliptin in treating hypertension through modulating serum vegf in diabetic hypertensive patients. J Cardiovasc Pharmacol Ther. 2019; 24(3): 254-261. doi: 10.1177/1074248418817345.
63. Derosa G, Cicero AF, Gaddi AV, Ciccarelli L, Piccinni MN, Salvadeo S, et al. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial. Clin Ther. 2005; 27(9): 1383-91. doi: 10.1016/j.clinthera.2005.09.003.
64. Licht CM, de Geus EJ, Seldenrijk A, van Hout HP, Zitman FG, van Dyck R, et al. Depression is associated with decreased blood pressure, but antidepressant use increases the risk for hypertension. Hypertension. 2009; 53(4): 631-8. doi: 10.1161/HYPERTENSIONAHA.108.126698.
65. Okuno T, Suzuki H, Saruta T. Dexamethasone hypertension in rats. Clin Exp Hypertens (1978). 1981; 3(5): 1075-86. doi: 10.3109/10641968109033722.
66. Dyba S, Tychowska I, Klukowska L, Nadulska A. The influence of baclofen on reflex circulatory reactions evoked by stimulation of the vagus nerve in the rabbit. Ann Univ Mariae Curie Sklodowska Med. 2002; 57(1): 67-73. PMID: 12898907.
67. Mesas AE, Leon-Muñoz LM, Rodriguez-Artalejo F, Lopez-Garcia E. The effect of coffee on blood pressure and cardiovascular disease in hypertensive individuals: a systematic review and meta-analysis. Am J Clin Nutr. 2011; 94(4): 1113-26. doi: 10.3945/ajcn.111.016667.
68. Kharb P, Mittal N, Gupta MC. Carbamazepine-induced hypertension: A rare case. Journal of Pharmacology and Pharmacotherapeutics. 2015; 6(4): 216-218. doi: 10.4103/0976-500x.171879.
69. Hiraichi E, Schiripa LN, Yamanouye N, Abdalla FM, Picarelli ZP. Effect of chymotrypsin on rat blood pressure. Gen Pharmacol. 1992; 23(4): 595-9. doi: 10.1016/0306-3623(92)90133-5.
70. Robert N, Wong GW, Wright JM. Effect of cyclosporine on blood pressure. Cochrane Database Syst Rev. 2010; 20; (1): CD007893. doi: 10.1002/14651858.CD007893.pub2.
71. Sigurdardóttir GR, Nilsson C, Odin P, Grabowski M. Cardiovascular effects of domperidone in patients with Parkinson's disease treated with apomorphine. Acta Neurol Scand. 2001; 104(2): 92-6. doi: 10.1034/j.1600-0404.2001.104002092.x.
72. Derby MA, Zhang L, Chappell JC, Gonzales CR, Callaghan JT, Leibowitz M, et al. The effects of supratherapeutic doses of duloxetine on blood pressure and pulse rate. J Cardiovasc Pharmacol. 2007; 49(6): 384-93. doi: 10.1097/FJC.0b013e31804d1cce.
73. Kanbay M, Akcay A, Delibasi T, Uz B, Kaya A, Koca C, et al. Comparison of effects of darbepoetin alfa and epoetin alfa on serum endothelin level and blood pressure. Adv Ther. 2007;24(2):346-52. doi: 10.1007/BF02849903.
74. Didion SP. Tacrolimus-induced hypertension: what's endothelial and hematopoietic FKBP12 got to do with it? Hypertension. 2011; 57(6): 1058-60. doi: 10.1161/HYPERTENSIONAHA.111.172320.
75. Sharkey PK, Rinaldi MG, Dunn JF, Hardin TC, Fetchick RJ, Graybill JR. High-dose itraconazole in the treatment of severe mycoses. Antimicrob Agents Chemother. 1991; 35(4): 707-13. doi: 10.1128/AAC.35.4.707.
76. Rozman B, Praprotnik S, Logar D, Tomšič M, Hojnik M, Kos-Golja M, et al. Leflunomide and hypertension. Annals of the Rheumatic Diseases 2002; 61: 567-569. doi: 10.1136/ard.61.6.567
77. Patil BM, Kulkarni NM, Unger BS. Elevation of systolic blood pressure in an animal model of olanzapine induced weight gain. Eur J Pharmacol. 2006; 551(1-3): 112-5. doi: 10.1016/j.ejphar.2006.09.009.
78. Zhang SH, Shen YX, Li L, Fan TT, Wang Y, Wei N. Phthalate exposure and high blood pressure in adults: a cross-sectional study in China. Environ Sci Pollut Res Int. 2018; 25(16): 15934-15942. doi: 10.1007/s11356-018-1845-1.
79. Isa AI, Felix S, Saleh MI, Muhammad A, Mohammed A, Mohammed KA, et al. Effect of theophylline on blood pressure of normotensive cats pre-administered with Adrenaline. IOSR Journal of Dental and Medical Sciences. 2014; 13: 116-120. doi: 10.9790/0853-1353116120
80. Benfenati F, Cortelli P, de Camillis M, Orlandi F, Forni C. Effects of sulpiride isomers in the control of blood pressure in man. Boll Soc Ital Biol Sper. 1980; 56(17) 1789-1794. PMID: 7459101.
81. Acharya LD, Rau NR, Udupa N, Surulivel Rajan M, Vijayanarayana K. Trends in Prescribing Antihypertensive Medications and Lipid Lowering Therapy in type-2 Diabetic Patients in South Indian Tertiary Care Hospital. Research J. Pharm. and Tech. 2016; 9(7):857-863.
82. Fravel MA, Ernst M. Drug interactions with antihypertensives. Curr Hypertens Rep. 2021; 23:14. doi:10.1007/s11906-021-01131-y
83. Venegas-Pont M, Ryan MJ. Can estrogens promote hypertension during systemic lupus erythematosus? Steroids. 2010; 75(11): 766-771. doi: 10.1016/j.steroids.2010.02.010.
84. Padmanabhan S, Paul L, Dominczak AF. The pharmacogenomics of anti-hypertensive therapy. Pharmaceuticals. 2010; 3(6): 1779-1791. doi:10.3390/ph3061779
85. Fan XL, Wang Y, Sun K, Zhang W, Yang XP, Wang SY, et al. Polymorphisms of ACE2 gene are associated with essential hypertension and antihypertensive effects of captopril in women. Clinical Pharmacology and Therapeutics. 2007; 82(2): 187-96. doi:10.1038/sj.clpt.6100214
86. Chen Q, Tang X, Yu CQ, Chen DF, Tian J, Cao Y, et al. Correlation of angiotensin-converting enzyme 2 gene polymorphism with antihypertensive effects of benazepril. Beijing Da Xue Xue Bao Yi Xue Ban. 2010; 42(3): 293-8. Chinese. PMID: 20559404.